Cannabis Law Report

MAY 26, 2022

Successful Behavioral Addiction Study Supplied Data for Patent. The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. The treatment was also well tolerated with no safety concerns. Awakn Life Sciences Corp. (

Treatment 52

Treatment Research and Development Therapy Data 52

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz and colleagues have published a paper summarizing ORR data from individuals with epilepsy in the medical journal Epilepsy & Behavior. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Even if there’s an accurate diagnosis, many mental health treatments have less-than-desirable efficacy, and there can be significant side effects.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Success rates of up to 80% have been observed for CBD related autism therapy.

Treatment 76

Treatment Oil CBD Therapy 76

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. Cancer therapy targets the cells that are dividing uncontrollably, while avoiding damage to the non-cancerous cells. How do we currently treat cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JANUARY 9, 2019

Now the former finance executive is on a mission to stamp out diabetes in some of the world’s worst-hit areas with a revolutionary marijuana treatment engineered by his firm, Phoenix Life Sciences International. It showed us there were ways to have formulas that were more effective for diabetes, and others for the treatment of cancers.”.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. “We Food and Drug Administration (FDA) for use in the U.S. In the U.S.,

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

The Cannigma

NOVEMBER 23, 2021

Listen & Subscribe: Finding the correct dosage and combination of cannabinoid products for medical treatment is almost universally a long and expensive process of trial and error. The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects.

Data 52

Data Patients Access Wellness and Beauty 52

Canna Law Blog

NOVEMBER 10, 2021

Psychedelics unicorn Compass Pathways released data for the largest clinical trial ever conducted of a psilocybin drug. Not only did the drug seem to work, but the heavily anticipated data were “ breathtaking ” in the words of Compass’ CEO. First, the trial data contained some problematic features, which I’ll address below.

Therapy 83

Therapy Data Clinical Trials Treatment 83

Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. billion in the next six years. .”

Therapy 109

Therapy Treatment Patients Policy 109

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Cannabis Law Report

SEPTEMBER 28, 2021

The data will then be analysed to recognise trends in responses. • Participants: The survey is open to all ACT residents over 18 years. • Use of Data and Feedback: The data will be used in my ANIP thesis and possibly for future research. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data.

Therapy 52

Therapy Medicine Data Collective 52

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. the laws surrounding the substance can be a little confusing.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

Cannabis Law Report

JUNE 12, 2021

She says the treatment did little but left her feeling numb and unable to heal. “The data was showing that psychedelics were providing benefits to people suffering from anxiety, depression, addiction and PTSD. The treatments were carefully dosed and conducted under medical supervision.

Therapy 105

Therapy Treatment Medicine Sleep 105

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Canna Law Blog

DECEMBER 16, 2021

The “purpose or general idea of bill” provides a good summary: this legislation would “create psilocybin service centers to provide innovative treatment options for ailments such as PTSD, depression, alcohol dependency, anxiety, among others.” Rules and Restrictions.

Legislation 96

Legislation Treatment Therapy Conditions 96

Cannabis Law Report

JULY 22, 2021

As regulations develop, the next phase of the Company’s strategy will involve the inclusion of alternative and psychedelic therapies into Levitee’s platform of traditional healthcare assets. This news release contains certain statements that may constitute forward-looking information under applicable securities laws.

eCommerce 105

eCommerce Therapy Media Access 105

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. It was the first published study assessing MDMA-Assisted Psychotherapy as a treatment for addiction. With a 20% relapse rate within the first nine months, compared to 75% relapse rate with traditional treatments.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Group Psilocybin Facilitation (8 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

DECEMBER 11, 2021

This reduction in prices will make the clinic the cheapest option for many patients looking to receive medical cannabis treatments for a wide variety of conditions and illnesses. Medical cannabis can be considered as a treatment for a number of conditions – including chronic pain, epilepsy, and insomnia – when first-line options have failed.

Access 52

Access Patients Chronic Pain Treatment 52

Veriheal

JANUARY 4, 2021

In adults with chronic pain , what are the harms of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the benefits of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the harms of cannabinoids?

Chronic Pain 104

Chronic Pain Therapy Cannabinoids Treatment 104

Cannabis Law Report

FEBRUARY 14, 2020

Consumer products law blog. Class actions against CBD companies proliferate under federal and state law. However, according to the federal Food, Drug & Cosmetic Act and FDA regulations and guidance, CBD products cannot be marketed as food additives, dietary supplements, or for therapeutic uses and treatment of diseases.

State Laws 59

State Laws Law CBD Food 59

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Zaid i , ANANDA’s Chief Executive Officer. “We

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

SEPTEMBER 12, 2021

Steve Sisolak signed Assembly Bill 101, making Nevada the first state to legalize the use of cannabinoids as a veterinary treatment. Because of the ambiguity in our law, I learned that many veterinarians chose not to talk about CBD with pet owners for fear of being disciplined,” Yeager said. Making sense of it all.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE:

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Complicating matters, each state has their own set of laws, which are rapidly evolving. Eric Rahn, Managing Director.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. George Goldsmith, CEO and Co-founder, COMPASS Pathways, said: “This 10 th patent is a strong testament to our innovation.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] More recently, MDMA therapy has inched closer to FDA approval. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 9, 2021

The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Healer

MARCH 26, 2021

For years, Tim Gresh took dozens of prescription opioid medications per day, seeking any relief for the debilitating back pain that he – no matter which medication or therapy he used – could just not shake. . “It Image: Derek Davis/Portland Press Herald Staff Photographer. It shattered my whole life,” the Windham resident said. .

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 29, 2021

It is well known that opioids are a huge driver of overdose deaths in the US and that a non-addictive therapy is a significant unmet need,” said Sohail R. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. Food and Drug Administration (FDA) for this trial.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52